admin • May 17, 2023
Lifestyle and Exercise in Hypertrophic Cardiomyopathy (LIVE-HCM) Results Released

Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy – JAMA Cardiology | Original Investigation

Exercise has well-established physical and mental health benefits and is an integral part of life for millions of people worldwide. However, for individuals with hypertrophic cardiomyopathy (HCM), the possibility that physical activity may heighten the risk of sudden cardiac death (SCD) has led to exercise restriction and disqualification from competitive sports.

HCM is defined by unexplained left ventricular hypertrophy (LVH) and has a worldwide prevalence of approximately 1 in 500 individuals.1 It is the most common genetic cardiomyopathy and is inherited as a mendelian trait in approximately 50% of patients, predominantly due to pathogenic variants in genes that encode sarcomeric proteins. In others, it is expressed as a complex trait with contributions from both polygenic and acquired factors. Some patients with HCM may experience symptoms of heart failure and atrial and/or ventricular arrhythmias, whereas others have normal longevity and good quality of life.

Results of this cohort study suggest that among individuals with HCM or those who are genotype positive/phenotype negative and are treated in experienced centers, those exercising vigorously did not experience a higher rate of death or life-threatening arrhythmias than those exercising moderately or those who were sedentary. These data may inform discussion between the patient and their expert clinician around exercise participation.

Click here to learn more.

Click here to view the recording of LIVE – HCM Study Discussion Webinar

Rachel Lampert, MD; Michael J. Ackerman, MD, PhD; Bradley S. Marino, MD; Matthew Burg, PhD;
Barbara Ainsworth, PhD, MPH; Lisa Salberg; Maria Teresa Tome Esteban, MD, PhD; Carolyn Y. Ho, MD;
Roselle Abraham, MD; Seshadri Balaji, MBBS, PhD; Cheryl Barth, BS; Charles I. Berul, MD; Martijn Bos, MD;
David Cannom, MD; Lubna Choudhury, MD; Maryann Concannon, MSW; Robert Cooper, MD;
Richard J. Czosek, MD; Anne M. Dubin, MD; James Dziura, PhD; Benjamin Eidem, MD; Michael S. Emery, MD;
N. A. Mark Estes, MD; Susan P. Etheridge, MD; Jeffrey B. Geske, MD; Belinda Gray, MBBS, PhD; Kevin Hall, MD;
Kimberly G. Harmon, MD; Cynthia A. James, PhD; Ashwin K. Lal, MD; Ian H. Law, MD; Fangyong Li, MS;
Mark S. Link, MD; William J. McKenna, MD; Silvana Molossi, MD, PhD; Brian Olshansky, MD;
Steven R. Ommen, MD; Elizabeth V. Saarel, MD; Sara Saberi, MD, MS; Laura Simone, MS; Gordon Tomaselli, MD;
James S. Ware, MD; Douglas P. Zipes, MD; Sharlene M. Day, MD; for the LIVE Consortium

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts